A phase i study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 1, 2010, Pages 69-74

  Center, Brian ^a   Petty, William Jeffrey ^a   Ayala, Diandra ^a   Hinson, William H ^a   Lovato, James ^a   Capellari, James ^a   Oaks, Timothy ^a   Miller, Antonius A ^a   Blackstock, Arthur William ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoradiation; Epidermal growth factor receptor; Lung cancer; Pulmonary toxicity

Indexed keywords

DOCETAXEL; GEFITINIB;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DIARRHEA; DRUG DOSE ESCALATION; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOXIA; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 76149123903     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181c59a0e     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Clamon G, Herndon J, Cooper R, et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:4-11.
3. Choy H, Akerley W, Safran H, et al. Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced nonsmall cell lung cancer. Semin Oncol 1996;23:117-119.
4. Akerley W, Choy H. Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer. Lung Cancer 1995;12(Suppl 2): S107-S115.
5. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III nonsmall- cell lung cancer: CALGB 30105. J Clin Oncol 2008;26:2457-2463.
6. Blackstock AW, Herndon JE II, Paskett ED, et al. Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Clin Oncol 2006;24:407-412.
7. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential versus concurrent chemoradiation for patients (Pts) with unresectable stage III non small cell lung cancer (NSCLC): initial report of the radiation therapy oncology group (RTOG) 9410. Proc ASCO 2000;19:484a.
8. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
9. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
10. Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995;13: 452-458.
11. Stinchcombe TE, Morris DE, Lee CB, et al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 2008;3:250-257.
12. Miller VA, Kris MG. Docetaxel (taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer. Semin Oncol 2000;27:3-10.
13. Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (taxotere) in synchronised HeLa cells. Br J Cancer 1995; 71:1194-1198.
14. Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (taxol) and docetaxel (taxotere) in HeLa and SQ20B cells. Cancer Res 1996;56:1842-1850.
15. Friedland D, Cohen J, Miller R Jr, et al. A phase II trial of docetaxel (taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999;26:19-23.
16. Miyake H, Hara S, Arakawa S, et al. Overexpression of Bcl-2 regulates sodium butyrate- and/or docetaxel-induced apoptosis in human bladder cancer cells both in vitro and in vivo. Int J Cancer 2001;93:26-32.
17. Magne N, Chargari C, Castadot P, et al. The efficacy and toxicity of EGFR in the settings of radiotherapy: focus on published clinical trials. Eur J Cancer 2008;44:2133-2143.
18. Bianco C, Bianco R, Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 2000;6:4343-4350. (Pubitemid 30840187)
19. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000;18:47S-53S.
20. Petty WJ, Dragnev KH, Memoli VA, et al. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 2004;10:7547-7554.
21. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
22. Brunsvig PF, Hatlevoll R, Berg R, et al. Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: a phase I/II study with 5 years' follow-up. Lung Cancer 2005;50:97-105.
23. Koukourakis MI, Kourousis C, Kamilaki M, et al. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer 1998;34:838-844.
24. Mauer AM, Masters GA, Haraf DJ, et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 1998;16:159-164.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
26. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-2456.
27. Hanna N, Neubauer M, Yiannoutsos C, et al; Hoosier Oncology Group; US Oncology. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26: 5755-5760.
28. Choong NW, Mauer AM, Haraf DJ, et al. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol 2008;3:1003-1011.
29. Ready N, Janne P, Herndon II J, et al. Chemoradiotherapy (CRT) and gefitinib (G) in stage III non small cell lung cancer (NSCLC): a CALGB stratified phase II trial. J Clin Oncol 2006;24:Abstract 7024.
30. Bhutani M, Pathak AK, Mao L. SWOG S0023: what meets the eye may be only half the truth. J Clin Oncol 2008;26:4848-4849; author reply 4850-14841
31. Azzariti A, Xu JM, Porcelli L, et al. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with gefitinib (Iressa, ZD1839). Biochem Pharmacol 2004;68: 135-144.
32. Chun PY, Feng FY, Scheurer AM, et al. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 2006;66:981-988.
33. Xu JM, Azzariti A, Severino M, et al. Characterization of sequencedependent synergy between ZD1839 ("Iressa") and oxaliplatin. Biochem Pharmacol 2003;66:551-563. (Pubitemid 37281274)
34. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784. (Pubitemid 41103588)
35. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794. (Pubitemid 41103589)
36. Herbst RS, Prager D, Hermann R, et al; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall- cell lung cancer. J Clin Oncol 2005;23:5892-5899.
37. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.